Family Management’s 10x Genomics TXG Stock Holding History

Family Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,912	Closed	-$285K	–	187
2021 Q4	$285K	Buy	+1,912	New	+$293K	0.07%	138

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Family Management's TXG Position: Q1 2022 in Review

Family Management sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 1,912 shares — an estimated $285K sold.

Family Management first reported a position in TXG in Q4 2021 and held it in 1 quarter. The position peaked at $285K in Q4 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

Family Management reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
Family Management sold 1,912 10x Genomics shares in Q1 2022, an estimated $285K.
Family Management first reported a position in 10x Genomics in Q4 2021 and held it in 1 quarter.
Family Management's 10x Genomics position peaked at $285K in Q4 2021.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Family Management's 13F filing for Q1 2022, filed 16 May 2022.